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Optineurin, a multifunctional protein involved in glaucoma, 
amyotrophic lateral sclerosis and antiviral signalling
Glaucomas are a heterogeneous group of neurodegenerative eye diseases that cause blindness and are one 
of the leading causes of blindness worldwide. Loss of vision in glaucoma occurs due to death of retinal 
ganglion cells (RGCs) in the optic nerve head (Quigley 1999). Some of the genes known to be involved 
in causing glaucoma in adults are myocilin, optineurin and WDR36 (Stone et al. 1997; Rezaie et al. 2002; 
Monemi et al. 2005; Ray and Mookherjee 2009). Mutations in the coding region of the gene OPTN, 
which codes for the protein optineurin, are associated with certain types of glaucoma. In the original 
study, families affected with normal tension glaucoma (a sub-type of adult onset primary open angle 
glaucoma) were analysed for mutations in optineurin (Rezaie et al. 2002). Subsequent studies have shown 
that in sporadic cases of glaucoma mutations in optineurin are rare, accounting for only about 1% of the 
cases. Almost all the glaucoma-associated mutations in OPTN are single copy alterations. Most of these 
mutations are missense mutations. One of the glaucoma-associated mutants (E50K) causes death of retinal 
ganglion cells in vitro as well as in transgenic mice providing support to the suggestion that mutations in 
optineurin cause glaucoma (Chalasani et al. 2007; Chi et al. 2010). 
A recent report described that certain mutations in optineurin are the cause of familial amyotrophic 
lateral sclerosis (ALS) (Maruyama et al. 2010). Like some forms of glaucomas, ALS is an adult onset 
progressive neurodegenerative disorder whose hallmark is the selective death of motor neurons of 
primary motor cortex, brainstem, and spinal cord. Mutations in optineurin were found in familial as well 
as sporadic cases of ALS. Three types of mutations were observed, two of these being homozygous. 
One of these homozygous mutations was deletion of exon 5, observed in familial ALS, and the other 
was Q398X nonsense mutation found in both familial as well sporadic cases. A heterozygous missense 
mutation E478G was observed in familial ALS (Maruyama et al. 2010). What are the functional defects 
caused by mutations in optineurin? To address this question we need to understand the function of normal 
optineurin.
Optineurin interacts with several proteins which are involved in various functions (table 1, fi gure 1). 
On the basis of interactions and other experiments various functions have been proposed for optineurin 
such as regulation of exocytosis and vesicle traffi c from the Golgi to the plasma membrane, organization 
of the Golgi stacks, regulation of signalling to transcription factor NF-κB, antiviral signalling, 
metabotropic glutamate receptor signalling and regulation of gene expression (Hattula and Peranen 2000; 
Anborgh et al. 2005; Weisschuh et al. 2007; Zhu et al. 2007; Chalasani et al. 2009; del Toro et al. 2009; 
Mankouri et al. 2010). Optineurin is phosphorylated on serine and tyrosine residues and exists as homo-
hexamers (Ying et al. 2010). Several optineurin-interacting proteins such as Rab8, Huntingtin, myosin 
VI and TBC1D17 are involved in regulating vesicular membrane traffi c in various cells. Knockdown of 
optineurin affects structure of the Golgi and reduces transport from the Golgi to the plasma membrane 
(Sahlender et al. 2005). However, there is no report of any disruption of this transport (from the
Golgi to the plasma membrane) or exocytosis by any disease-associated mutant although overexpression 
of the E50K mutant and to a lesser extent of wild-type optineurin causes breakdown of the Golgi
(Park et al. 2006). Recently we and others have shown that knockdown of optineurin reduces endocytic 
traffi cking of transferrin and its receptor (transferrin receptor, TfR) to the recycling endosomes 
(Nagabhushana et al. 2010; Park et al. 2010). A glaucoma-causing mutant of optineurin (E50K) impairs 
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traffi cking of TfR possibly due to altered interactions with Rab8 and transferrin receptor. This impaired 
traffi cking results in accumulation of TfR in large vesicular structures formed by E50K leading to lower 
level of TfR at the cell surface and hence reduced uptake of transferrin by the E50K expressing cells. 
It was suggested that impaired traffi cking caused by the E50K mutant might be the cause of cell death 
induced by this mutant in RGCs (Nagabhushana et al. 2010; Park et al. 2010). Transport of neurotrophins 
in the axons is crucial for the survival of neuronal cells. Blockade of axonal transport has been reported 
in glaucoma in humans and in experimental animal models (Pease et al. 2000). However, the molecules 
whose defective traffi cking by E50K optineurin causes RGC death in glaucoma need to be identifi ed. 
Is the defective traffi cking of neurotrophins, transferrin or their receptors (or some other associated 
molecules) responsible for RGC death?
Another function of optineurin is regulation of signalling to the transcription factor NF-κB. NF-κB plays 
a key role in the expression of many genes involved in regulating immune response, apoptosis, cell cycle 
and its deregulation is involved in the pathogenesis of many diseases including some neurodegenerative 
disorders. Upon treatment of cells with TNFα, trimerization of TNF receptor results in the assembly of a 
signalling complex at the cytoplasmic side of the plasma membrane. In this complex RIP is ubiquitinated 
(by the addition of Lys63-linked ubiquitin chains) which then recruits NF-κB essential modulator (NEMO), 
the regulatory sub-unit of a kinase complex, IKK. This leads to activation of the catalytic subunits
of the IKK complex, IKKα and β, that phosphorylate inhibitor of κB (IκB) resulting in its degradation. 
This enables nuclear translocation of NF-κB to activate transcription of target genes (Hayden and
Ghosh 2008). Knockdown of optineurin increases basal as well as TNFα-induced NF-κB activity
whereas overexpressed optineurin inhibits it. This negative regulation of NF-κB activity is believed
to be the result of competition of optineurin with NEMO for binding to polyubiquitinated RIP (Zhu et al. 
2007). C-terminal half of optineurin shows considerable homology with NEMO. However the regulation 
of NF-κB activity by optineurin is likely to be far more complex because optineurin interacts with two 
other negative regulators of NF-κB- CYLD, a deubiquitinase and A20, a ubiquitin editing enzyme 
(Chalasani et al. 2009). In human T-lymphotropic virus type 1 (HTLV-1) infected cells optineurin interacts 
with TAX1BP1 and a viral protein TAX1 resulting in sustained activation of NF-κB and ubiquitination of 
TAX1 (Journo et al. 2009). Thus role of optineurin in the regulation of NF-κB is cell type and stimulus 
dependent.
Figure 1. Schematic representation of optineurin showing domain organization, key mutations and binding sites of interacting proteins. 
(A) A schematic showing various domains of optineurin and the locations of glaucoma (red ) and ALS associated (blue ) mutations. 
M98K is a polymorphism. (B) Interacting proteins of optineurin and their binding sites on optineurin. CC, coiled coil; LZ, leucine zipper; 
UBD, ubiquitin-binding domain; ZF, zinc fi nger.
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Do the glaucoma- and ALS-associated mutations affect distinct aspects of cellular functions of optineurin 
(membrane traffi cking, NF-κB signalling)? All the three ALS associated mutants of optineurin showed no 
inhibition of basal as well as TNFα-induced NF-κB activity although wild-type optineurin showed good 
inhibition. These experiments were done in mouse NSC-34 cells, a neuroblastoma and spinal-cord hybrid 
cell line relevant for ALS (Maruyama et al. 2010). The authors suggest that defective NF-κB regulation 
by mutants of optineurin may be contributing to ALS. In contrast, the glaucoma-associated E50K mutant 
attenuates TNFα induced NF-κB activation more strongly than wild-type optineurin (Sudhakar et al. 
2009). Both hyperactivation and severe inhibition of NF-κB have been proposed to be responsible for 
neurodegeneration (Mattson and Meffert 2006). The effect of ALS-associated mutations of optineurin 
on vesicle traffi cking is yet to be analysed. Since ubiquitin-binding domain (UBD) is required for both 
endocytic traffi cking as well as NF-κB regulation, the Q398X (which lacks UBD) and E478G (which 
is likely to have lost the function of UBD) mutants may be defective in vesicle traffi cking. The E478G 
mutant shows altered sub-cellular distribution which appears to be similar to the localization pattern of 
UBD-defective D474N mutant (Maruyama et al. 2010; Nagabhushana et al. 2010).
What is the mechanism by which mutations in optineurin cause ALS? The dominant and recessive 
mutations are likely to cause ALS by different mechanisms. In case of recessive mutations the level 
of optineurin protein will decrease and loss of functions of optineurin is likely to cause the disease. 
The dominant heterozygous mutation E478G showed increased optineurin protein in the cell body 
and neurites, and also showed different sub-cellular distribution (Maruyama et al. 2010). The authors 
suggested that increased NF-κB activity caused by mutation in optineurin and/or impaired intracellular 
traffi cking may be contributing to the disease pathogenesis. Increased NF-κB activity has been reported in 
sporadic ALS motor neurons which may increase optineurin protein level because NF-κB is involved in 
inducing optineurin gene expression by activating the promoter (Sudhakar et al. 2009).
Neuropathology of ALS, like some other neurodegenerative diseases, is characterized by large 
intracytoplasmic aggregates or inclusions of largely ubiquitinated proteins. Motor neurons from a 
subject with E478G mutation (familial ALS) showed intracytoplasmic inclusions which were optineurin 
Table 1. Optineurin interacting proteins and their functions
Interacting protein Function References
Rab8 Vesicular traffi cking, cellular morphogenesis Hattula and Peranen 2000 
Myosin VI Exocytosis, Golgi morphogenesis, polarized EGFR 
traffi cking and migration
Sahalender et al. 2005 
Chibalina et al. 2010
Huntingtin Vesicular traffi cking, post Golgi traffi cking to 
lysosome
Del Toro et al. 2009
Transferrin receptor Endocytic recycling Nagabhushana et al. 2010, 
Park et al. 2010
RIP1 NF-κB signalling Zhu et al. 2007
TRAF3 IFN-β induction and antiviral responses Mankouri et al. 2010
TBK1 IFN-β induction and antiviral responses Mankouri et al. 2010
Morton et al. 2008
TAX1BP1 NF-κB signalling Journo et al. 2009
TAX1 and TAX2 HTLV- mediated NF-κB activation Journo et al. 2009
mGluR1, mGluR5 Metabotropic glutamate signalling Anborgh et al. 2005
TFIIIA Transcription? Moreland et al. 2000
CYLD NF-κB signalling? Chalasani et al. 2009
A20 NF-κB signalling? Chalasani et al. 2009
TBC1D17 Vesicular traffi cking? Chalasani et al. 2009
UXT NF-κB signalling? Chalasani et al. 2009
ZBTB33 Cell growth and development Chalasani et al. 2009
BAT4 Immunity Chalasani et al. 2009
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positive. These inclusions were also positive for ubiquitin, a constituent of inclusions seen in many 
neurodegenerative diseases. Interestingly these optineurin positive inclusions were also seen in some 
cases of sporadic ALS in which optineurin was not mutated but other genes (SOD1, TDP-43) were 
mutated (Maruyama et al. 2010). Therefore optineurin may have a much broader role in ALS. The 
vesicular structures or foci formed by the glaucoma-causing mutant E50K and to a lesser extent wild-type 
optineurin are positive for ubiquitin. The E50K mutant increases ubiquitination of transferrin receptor 
(Nagabhushana et al. 2010). Thus one of the functions of mutated optineurin in ALS and glaucoma may 
be to increase ubiquitination. Overexpression of mutant huntingtin disrupts interaction of optineurin and 
Rab8 and their localization to the Golgi disrupting traffi cking from TGN to lysosomes thereby inducing 
formation of autophagosomes (del Toro et al. 2009). The role of optineurin in autophagosome formation 
and its relevance to glaucoma or ALS, if any, needs further investigation. 
In response to viral infection our innate immune system produces type I interferons (IFNα/IFNβ) which 
activate transcription of many genes to produce antiviral state in the host cells. However, a tight regulation 
of cytokine signalling is vital to limit unwarranted infl ammatory tissue damage. Loss of IFNβ production 
can lead to immunodefi ciency leading to reduced ability of the host to combat viral infection. Optineurin 
negatively regulates the production of IFNβ in response to RNA virus infection and this signalling involves 
interaction of optineurin with antiviral protein kinase TBK1 and ubiquitin ligase TRAF3 (Mankouri et al. 
2010). These authors suggest that optineurin may be a general negative regulator of infl ammation and 
a potential target for antiviral therapy. In accordance with this, a recent genome wide association study
has found that optineurin is associated with Paget disease, an infl ammatory disease of the bone
(Albagha et al. 2010). 
Thus the two major functions regulated by optineurin are membrane traffi cking and signalling to 
transcription factor NF-κB. Optineurin interacts with diverse array of proteins and, like huntingtin, acts 
as a platform to assemble multimolecular complexes to mediate various cellular and molecular functions. 
Altered interactions of optineurin mutants with cellular proteins may be the main cause for defective 
functions leading to disease phenotype. Since the level of optineurin is regulated, altered level of optineurin 
due to mutation or other factors may also contribute to disease pathogenesis. Ubiquitin-binding function 
of optineurin and regulation of ubiquitination of cellular proteins by optineurin are likely to be crucial for 
normal cell physiology and disease pathogenesis caused by mutations in optineurin. Differential effects of 
mutations on various functions of optineurin may be responsible for the selectivity of disease phenotype.
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